Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Ulcerative Colitis

In brief

The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Key facts

Study ID
NCT02536404
Run by
Arena Pharmaceuticals
People needed
118
Starts
2016-01-25
Expected to finish
2018-11-01
Last updated by the study team
2021-11-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.